[1]
|
Jiang, M., Guo, X., Yuan, L., et al. (2020) Killer Cell Immunoglobulin-Like Receptor Gene Cluster Predisposes to Sus-ceptibility to B-Cell Acute Lymphoblastic Leukemia in Chinese Children. International Journal of Clinical and Experi-mental Pathology, 13, 536-542.
|
[2]
|
Rabilloud, T., Potier, D., Pankaew, S., et al. (2021) Single-Cell Profiling Identifies Pre-Existing CD19-Negative Subclones in a B-ALL Patient with CD19-Negative Relapse after CAR-T Therapy. Nature Communications, 12, Article No. 865. https://doi.org/10.1038/s41467-021-21168-6
|
[3]
|
Alsagaby, S.A. (2019) Omics-Based Insights into Therapy Failure of Pediatric B-Lineage Acutes Lymphoblastic Leukemia. Oncology Reviews, 13, 149-155. https://doi.org/10.4081/oncol.2019.435
|
[4]
|
Goroshchuk, O., Vidarsdottir, L., Björklund, A.C., et al. (2020) Targeting Plk1 with siRNNs in Primary Cells from Pediatric B-Cell Acute Lymphoblastic Leukemia Patients. Scientific Reports, 10, Article No. 2688.
https://doi.org/10.1038/s41598-020-59653-5
|
[5]
|
Contreras, C.F., Higham, C.S., Behnert, A., et al. (2021) Clinical Utilization of Blinatumomab and Inotuzumab Immunotherapy in Children with Relapsed or Refractory B-Acute Lympho-blastic Leukemia. Pediatric Blood & Cancer, 68, e28718. https://doi.org/10.1002/pbc.28718
|
[6]
|
Fabrizio, V.A., Phillips, C.L., Lane, A., et al. (2022) Tisagenlecleucel Outcomes in Relapsed/Refractory Extramedullary ALL: A Pediat-ric Real World CAR Consortium Report. Blood Advances, 6, 600-610.
https://doi.org/10.1182/bloodadvances.2021005564
|
[7]
|
Hoffman, L.M. and Gore, L. (2014) Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE® Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications. Frontiers in Oncology, 4, Article 63. https://doi.org/10.3389/fonc.2014.00063
|
[8]
|
Queudeville, M. and Ebinger, M. (2021) Blinatumomab in Pediatric Acute Lymphoblastic Leukemia—From Salvage to First Line Therapy (A Systematic Review). Journal of Clinical Medi-cine, 10, Article 2544.
https://doi.org/10.3390/jcm10122544
|
[9]
|
Topp, M.S., Zimmerman, Z., Cannell, P., et al. (2018) Health-Related Quality of Life in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia Treated with Blinatumomab. Blood, 131, 2906-2914.
https://doi.org/10.1182/blood-2017-09-804658
|
[10]
|
Brischwein, K., Schlereth, B., Guller, B., et al. (2006) MT110: A Novel Bispecific Single-Chain Antibody Construct with High Efficacy in Eradicating Established Tumors. Molecular Immunology, 43, 1129-1143.
https://doi.org/10.1016/j.molimm.2005.07.034
|
[11]
|
解姣, 杜薇薇, 刘素香, 等. 贝林妥欧单抗治疗儿童复发急性B淋巴细胞白血病3例临床分析[J]. 中国小儿血液与肿瘤杂志, 2022, 27(6): 379-382.
|
[12]
|
Duffy, C., Santana, V., Inaba, H., et al. (2022) Evaluating Blinatumomab Implementation in Low- and Middle-Income Countries: A Study Protocol. Implementation Science Communications, 3, Article No. 62.
https://doi.org/10.1186/s43058-022-00310-5
|
[13]
|
Pawinska-Wasikowska, K., Wieczorek, A., Balwierz, W., et al. (2022) Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia. Cancers, 14, Article 458. https://doi.org/10.3390/cancers14020458
|
[14]
|
Brown, P.A., Ji, L., Xu, X., et al. (2021) Effect of Postreinduction Therapy Consolidation with Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults with First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. Journal of the American Medical Association, 325, 833-842.
https://doi.org/10.1001/jama.2021.0669
|
[15]
|
Nguyen, K., Devidas, M., Cheng, S.C., et al. (2008) Factors Influ-encing Survival after Relapse from Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study. Leukemia, 22, 2142-2150. https://doi.org/10.1038/leu.2008.251
|
[16]
|
Chinese Medical Association (2022) Chinese Consensus for the Bispeific T Cell Engager in the Treatment of B-Cell Acute Lymphoblastic Leukemia (2022). Chinese Journal of He-matology, 43, 448-455.
|
[17]
|
Elitzur, S., Arad-Cohen, N., Barzilai-Birenboim, S., et al. (2019) Blinatumomab as a Bridge to Further Therapy in Cases of Overwhelming Toxicity in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia: Report from the Israeli Study Group of Childhood Leukemia. Pediatric Blood & Cancer, 66, e27898. https://doi.org/10.1002/pbc.27898
|
[18]
|
游红亮, 李远方, 路娜丹, 等. 贝林妥欧单抗治疗儿童急性B淋巴细胞白血病10例临床分析[J]. 中华实用儿科临床杂志, 2023, 38(7): 538-541.
|
[19]
|
Chitadze, G., Laqua, A., Lettau, M., Baldus, C.D. and Brüggemann, M. (2020) Bispecific Antibodies in Acute Lymphoblastic Leukemia Therapy. Expert Re-view of Hematology, 13, 1211-1233.
https://doi.org/10.1080/17474086.2020.1831380
|
[20]
|
Liu, D.L., Zhao, J.J., Song, Y.P., Luo, X.F. and Yang, T. (2019) Clinical Trial Update on Bispecific Antibodies, Antibody-Drug Conjugates, and Antibody-Containing Regimens for Acute Lymphoblastic Leukemia. Journal of Hematology & Oncology, 12, Article No. 15. https://doi.org/10.1186/s13045-019-0703-z
|
[21]
|
Sigmund, A.M., Sahasrabudhe, K.D. and Bhatnagar, B. (2020) Evaluating Blinatumomab for the Treatment of Relapsed/Refractory All: Design, Development, and Place in Therapy. Blood and Lymphatic Cancer: Targets and Therapy, 10, 7-20. https://doi.org/10.2147/BLCTT.S223894
|
[22]
|
Kiyoi, H., Morris, J.D., Oh, I., et al. (2020) Phase 1b/2 Study of Blinatumomab in Japanese Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia. Cancer Science, 111, 1314-1323. https://doi.org/10.1111/cas.14322
|